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ABSTRACT  Ϯϰ 
In chronic respiratory disease the formation of dense, 3-dimensional ‘micro colonies’ by Ϯϱ 
Pseudomonas aeruginosa within the airway plays an important role in contributing to Ϯϲ 
resistance to treatment.  An in vitro biofilm model of pseudomonal microcolony formation Ϯϳ 
using artificial sputum (AS) medium was established to study the effects of low molecular Ϯϴ 
weight alginate oligomers (OligoG CF-5/20) on pseudomonal growth, microcolony formation Ϯϵ 
and the efficacy of colistin.  The studies employed clinical cystic fibrosis (CF) isolates (n=3) ϯϬ 
and reference non-mucoid and mucoid multi-drug resistant (MDR) CF isolates (n=7).  ϯϭ 
Bacterial growth, biofilm development and disruption were studied using cell-viability assays ϯϮ 
and image analysis using scanning electron- and confocal laser scanning microscopy.  ϯϯ 
Pseudomonal growth in AS medium was associated with increased ATP production (p<0.05) ϯϰ 
and the formation (at 48 h) of discrete (>10 µm) microcolonies.  In conventional growth ϯϱ 
medium, colistin retained an ability to inhibit growth of planktonic bacteria, although the MIC ϯϲ 
was increased (0.1 to 0.4 µg/ml) in AS medium versus.  In contrast, in an established biofilm ϯϳ 
model in the AS medium, the efficacy of colistin was decreased.  OligoG CF-5/20 (>2%) ϯϴ 
treatment however, induced dose-dependent biofilm disruption (p<0.05), and led to colistin ϯϵ 
retaining its antimicrobial activity (p<0.05).  Whilst circular dichroism indicated that OligoG ϰϬ 
CF-5/20 did not change the orientation of the alginate carboxyl groups, mass-spectrometry ϰϭ 
demonstrated that the oligomers induced dose-dependent (>0.2%; p<0.05) reductions in ϰϮ 
pseudomonal quorum sensing signaling.  These findings reinforce the potential clinical ϰϯ 
significance of microcolony formation in the CF lung, and highlight a novel approach to treat ϰϰ 
MDR pseudomonal infections. ϰϱ 
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The opportunistic Gram-negative pathogen Pseudomonas aeruginosa is found in a range of ϱϬ 
chronic human respiratory diseases, including chronic obstructive pulmonary disease and ϱϭ 
cystic fibrosis (CF) (1).  CF is a life-threatening, autosomal recessive genetic disorder ϱϮ 
affecting 1 in 2,300 Caucasian live births (2).  Reduced airway surface-liquid volume and ϱϯ 
abnormally viscous sputum result in ineffective mucociliary clearance (3).  Chronic bacterial ϱϰ 
colonization of the lung by a number of opportunist pathogens occurs, most notably P. ϱϱ 
aeruginosa, which will predominate with time (4). ϱϲ 
Within the diseased lung, patho-adaptive mutation results in the selection of ϱϳ 
hypermutator P. aeruginosa strains (5, 6).  In P. aeruginosa this adaption occurs with a ϱϴ 
switch to the mucoid phenotype, characterized by over-production of high molecular weight ϱϵ 
(Mw; >15 kDa) alginate exopolysaccharide (EPS) (7, 8).  This switch is accompanied by ϲϬ 
modification of acyl homoserine lactone (AHL) and Pseudomonas quinolone signal (PQS)-ϲϭ 
dependent quorum sensing (QS) systems (λ), with altered production of virulence factors ϲϮ 
e.g. pyocyanin and hydrogen cyanide (10).  Extracellular alginate affords protection from ϲϯ 
host innate immune-responses, including phagocytosis and neutrophil-derived reactive ϲϰ 
oxygen species (11).  Mucoidal pseudomonal strains are often un-responsive to aggressive ϲϱ 
antibiotic selection (12) and  18.1% of CF patients are colonized with multi-drug resistant ϲϲ 
(MDR) P. aeruginosa (13). ϲϳ 
In contrast to standard laboratory models of bacterial biofilm formation on material ϲϴ 
surfaces, biofilms within the CF lung form as non-adherent spherical microcolonies, ϲϵ 
embedded in respiratory mucin (14, 15).  Whilst in vitro studies of P. aeruginosa from CF ϳϬ 
lungs routinely employ nutrient-rich media to optimize bacterial growth, or Mueller-Hinton ϳϭ 
(MH) medium, such media fail to adequately reproduce the lung environment or secretome ϳϮ 
(3).  More recently, defined media such as artificial sputum (AS) medium (containing ϳϯ 
components of CF sputum e.g. DNA, mucin, mineral salts, proteins and amino acids) have ϳϰ 
been employed to model the behavior of P. aeruginosa (16-18).  These AS medium models ϳϱ 
have been used to study the adaptation of pathogens to the CF lung using whole-genome ϳϲ 
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sequencing and microarray expression profiling (1λ), analyze diffusion (20) and test the ϳϳ 
effectiveness of antibacterial therapeutics (21). ϳϴ 
This distinctive biofilm microcolony formation in the CF lung has been demonstrated ex-ϳϵ 
vivo in freshly-excised intraluminal material and in lung sections (14).  Studies have also ϴϬ 
further shown that in vitro biofilms observed in nutrient-limited conditions are increasingly ϴϭ 
recalcitrant to antibiotic therapy due to enhanced tolerance  (22).  The design and delivery of ϴϮ 
antimicrobial therapy targeted against the polymicrobial respiratory biofilm is, therefore, ϴϯ 
challenging (23).  ϴϰ 
The acquisition of MDR Pseudomonas in the CF lung has led to a resurgence of clinical ϴϱ 
interest in the bacteriocidal antibiotic colistin (24).  Overlooked for many years due to ϴϲ 
associated nephro- and neuro-toxicity (25, 26), colistin is increasingly used to treat life-ϴϳ 
threatening infections (24) and as an inhaled therapy in CF to prevent establishment of ϴϴ 
infection by MDR bacteria (25).  While resistance to colistin remains low (27), the emergence ϴϵ 
of colistin-resistant strains heralds fears of a post-antibiotic era (28). ϵϬ 
We previously described the use of a low molecular weight alginate oligomer (OligoG ϵϭ 
CF-5/20, ≥ 85% guluronic acid, with a degree of polymerization [DPn] of 16; Mn 3,200) from ϵϮ 
the seaweed Laminaria hyperborea as a promising novel therapy in CF (2λ-31).  In vitro ϵϯ 
studies, demonstrated the ability of OligoG CF-5/20 to modify bacterial surface charge (30) ϵϰ 
and biofilm growth of non-mucoid Pseudomonas sp. in conventional culture/biofilm models ϵϱ 
(2λ).  It is however, important to determine whether OligoG CF-5/20 could modify bacterial ϵϲ 
growth within the inherently antibiotic-resistant microcolonies, which characterize the ϵϳ 
diseased CF lung. ϵϴ 
The objective of this study was to investigate the therapeutic efficacy of OligoG CF-5/20 ϵϵ 
and colistin in an in vitro microcolony model.  We characterized the growth of fresh clinical ϭϬϬ 
isolates from CF patients and strains from the International P. aeruginosa Reference Panel ϭϬϭ 
(IPARP).  Planktonic and biofilm cultures of wild-type PAO1 and the mucoid MDR ϭϬϮ 
NH57388A were studied in MH and AS media.  We developed microcolonies in the AS ϭϬϯ 
medium and investigated the ability of OligoG CF-5/20 to modify these biofilms and further ϭϬϰ 
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determined the effectiveness of a combination treatment with colistin.  The effect of colistin ϭϬϱ 
on the mucoid CF isolate NH57388A grown under planktonic and biofilm conditions was ϭϬϲ 
reduced in this AS medium.  In contrast, OligoG CF-5/20 retained its dose-dependent anti-ϭϬϳ 
biofilm properties, as well as maintaining the effectiveness of colistin in vitro, demonstrating ϭϬϴ 
that addition of alginate oligosaccharides modifies pseudomonal microcolony assembly.  ϭϬϵ 
ϭϭϬ 
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RESULTS  ϭϭϭ 
Non-mucoid P. aeruginosa IPARP have faster growth rates in MH medium than either ϭϭϮ 
mucoid or new non-mucoid CF isolates  ϭϭϯ 
Growth of non-mucoid P. aeruginosa in MH medium from the IPARP reference strains was ϭϭϰ 
more abundant (maximum absorbance ≥1) compared to the delayed, weaker growth of the ϭϭϱ 
fresh clinical isolates (maximum absorbance ≤1); acquiring stationary phase at 12 h versus ϭϭϲ 
20 h respectively (Fig. 1A).  The growth rates of the non-mucoid P. aeruginosa (PAO1, AA2, ϭϭϳ 
AA44) were also greater than those of the new CF Isolates (22476, 22078, 22554) and those ϭϭϴ 
of the mucoidal strains (AA43, IST27, 21λ2, NH57388A) from the IPARP collection (Fig. 1B) ϭϭϵ 
having doubling-times (at maximum exponential growth) of 0.2-0.23 versus 0.31-0.6 versus ϭϮϬ 
0.2λ-0.56 unit/h respectively.   ϭϮϭ 
 ϭϮϮ 
Colistin maintains its antimicrobial properties in the presence of the mucolytic OligoG ϭϮϯ 
CF-5/20 ϭϮϰ 
Initial studies on the effect of OligoG CF-5/20 and colistin (0.5x minimum inhibitory ϭϮϱ 
concentration [MIC] value) on pseudomonal growth in MH medium, demonstrated no ϭϮϲ 
difference in the growth rate of NH57388A when treated with colistin (0.16 unit/h) compared ϭϮϳ 
to the control (Fig. 1C), although a reduced growth rate (0.12 unit/h) was noted when treated ϭϮϴ 
with either 2% OligoG CF-5/20 or colistin with 2% OligoG CF-5/20.  This was reflected by the ϭϮϵ 
significantly decreased cell biomass at stationary phase (36 h) following treatment with 2% ϭϯϬ 
OligoG CF-5/20 in combination with colistin compared to the control (p<0.05). ϭϯϭ 
In the biofilm disruption assay, confocal laser scanning microscopy (CLSM) images of ϭϯϮ 
LIVE/DEAD®-stained, 24 h established pseudomonal biofilms demonstrated homogenous ϭϯϯ 
growth in the untreated control (Fig. 1D).  Treatment for 1 h with colistin alone at 0.5x the ϭϯϰ 
minimum biofilm eradication concentration (MBEC value as previously described [32]) was ϭϯϱ 
associated with a decreased density of the resultant biofilm (Fig. 1E).  Furthermore, when ϭϯϲ 
treated with 2% OligoG CF-5/20 alone for 1 h, the biofilm height was reduced and there was ϭϯϳ 
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increased porosity (Fig. 1F).  Combination treatment of colistin and 2% OligoG CF-5/20 ϭϯϴ 
resulted in marked biofilm disruption (Fig. 1G).  Quantification using COMSTAT image ϭϯϵ 
analysis software (33) revealed that biofilm height was significantly reduced from 11 ±4 µm ϭϰϬ 
(in the untreated control) to 1.1 ±0.2 µm following 2% OligoG CF-5/20 and colistin  ϭϰϭ 
combination treatment (Fig. 1H).  In parallel, the ratio of dead to live cells was significantly ϭϰϮ 
increased following treatment with colistin (0.24 ±0.07) or 2% OligoG CF-5/20 and colistin in ϭϰϯ 
combination (0.4λ ±0.22) compared to the control (0.053 ±0.014; p<0.05; Fig. 1I); with ϭϰϰ 
associated increases in porosity.   ϭϰϱ 
 ϭϰϲ 
Mucoid and non-mucoid P. aeruginosa show a distinctly altered biofilm phenotype ϭϰϳ 
in artificial sputum medium ϭϰϴ 
Biofilms grown in different nutrient media exhibited distinct patterns of growth, with a marked ϭϰϵ 
phenotypic difference in biofilm architecture in MH- versus AS medium (Fig. 2A-B; ϭϱϬ 
diagrammatic representation Fig. 2C).  Pseudomonal biofilms of both strains showed ϭϱϭ 
conventional homogenous growth in MH medium, whilst discrete, spherical microcolonies ϭϱϮ 
with an inter-linking network of extracellular polysaccharide (EPS) were apparent in AS ϭϱϯ 
medium.  Microcolonies were not strongly bound to the well plates and varied considerably ϭϱϰ 
in size.  The median diameter of the PAO1 and NH57388A microcolonies was 14 ± 4 µm ϭϱϱ 
and 11 ±5 µm respectively; the difference in size perhaps reflecting the slower growth rate of ϭϱϲ 
the mucoid strain.  Elongated structures between the microcolonies were composed of ϭϱϳ 
linearly arranged bacterial cells.   ϭϱϴ 
Growth curves were performed using a cell-viability assay, (measuring ATP production); ϭϱϵ 
conventional growth curves with optical density measurements being impractical in AS ϭϲϬ 
medium, due to bacterial aggregation and microcolony formation.  Marked differences in ϭϲϭ 
ATP production between cells grown in AS versus MH medium were evident within 24 h, ϭϲϮ 
being considerably elevated in AS medium (Fig. 2D).     ϭϲϯ 
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 ϭϲϰ 
OligoG CF-5/20 disrupts P. aeruginosa (NH57388A) microcolony formation in artificial ϭϲϱ 
sputum medium  ϭϲϲ 
SEM studies using a biofilm formation assay of P. aeruginosa (NH57388A) biofilms grown in ϭϲϳ 
MH medium ± OligoG CF-5/20 demonstrated the growth inhibitory effects of OligoG CF-5/20 ϭϲϴ 
at ≥2% (w/v; Fig. 3A), which was reflected in a corresponding reduction in EPS formation.  ϭϲϵ 
Mucoid P. aeruginosa (NH57388A) formed typical microcolonies in AS medium at 48 h (Fig. ϭϳϬ 
3B); with individual bacterial cells visible on the surface of the microcolonies encased in EPS ϭϳϭ 
(Fig. 3C).  Biofilm formation in the presence of OligoG CF-5/20 was associated with a dose-ϭϳϮ 
dependent decrease in microcolony size and increasing cellular disruption of the biofilms.  At ϭϳϯ 
6% OligoG CF-5/20, the median microcolony diameter was 4.5 µm versus 6.6 µm in the ϭϳϰ 
untreated control (Fig. 3D).  Corresponding CLSM images of Syto-λ and Concanavalin A ϭϳϱ 
633 matrix-stained NH57388A 48 h biofilms in AS medium showed dense microcolonies ϭϳϲ 
surrounded by EPS (red) throughout the structure (Fig. 3E).  Biofilms grown in OligoG CF-ϭϳϳ 
5/20 exhibited a decreased, overall biofilm mass with few spherical microcolonies and ϭϳϴ 
reduced EPS. ϭϳϵ 
Using the biofilm disruption assay, CLSM images of matrix-stained NH57388A 48 h-ϭϴϬ 
established biofilms stained with Syto-λ (green) demonstrated large cellular aggregates or ϭϴϭ 
microcolonies (Fig. 3F) on (or within) a layer of cells.  Treatment for 1 h with 2% OligoG CF-ϭϴϮ 
5/20, induced a reduction in aggregate size (Fig. 3G), with marked microcolony disruption.  ϭϴϯ 
3D videos of these images are available online (Supplementary information Video 1). ϭϴϰ 
 ϭϴϱ 
 ϭϴϲ 
Circular dichroism spectra of OligoG CF-5/20 mixed with high molecular weight ϭϴϳ 
pseudomonal alginate do not indicate a specific interaction  ϭϴϴ 
Circular dichroism (CD) spectroscopy was used to test whether OligoG CF-5/20 and the high ϭϴϵ 
molecular weight EPS alginate produced by mucoid pseudomonal strains show a specific ϭϵϬ 
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interaction.  The CD chromophore responsible for the Cotton effect observed at ca. 210 nm ϭϵϭ 
has been identified as the carboxyl groups of the alginates, and the n → π* transition reflects ϭϵϮ 
their orientation (34).  Upon heating from 4 to 37°C, spectra of high Mw alginate showed no ϭϵϯ 
changes over a period of ~80 min (Fig. 4A, scans 1 to 7).  Subsequent addition of OligoG ϭϵϰ 
CF-5/20 at a 50-fold molar excess resulted in an increased CD amplitude, i.e. more negative ϭϵϱ 
values (Fig. 4A, scans 8 to 11).  Addition of Ca2+ to a final concentration of 1 mM had no ϭϵϲ 
effect (Fig. 4A, scans 12 to 17).  The spectra observed for the high Mw alginate/OligoG CF-ϭϵϳ 
5/20 mixture corresponded to an additive effect of the two components not indicating any ϭϵϴ 
change in the orientation of the carboxyl groups (cf. dashed curves in Fig. 4A).  Experiments ϭϵϵ 
in which Ca2+ was added to the high Mw alginate before the addition of OligoG CF-5/20, and ϮϬϬ 
a 1μ600 molar ratio of high Mw alginate to OligoG CF-5/20 also are compatible with an ϮϬϭ 
additive effect with no indication of a change in the orientation of the carboxyl groups (Fig. ϮϬϮ 
S1). ϮϬϯ 
 ϮϬϰ 
OligoG CF-5/20 affects cell-signaling in pseudomonal biofilms ϮϬϱ 
To determine whether OligoG CF-5/20 affected these changes via modification of QS ϮϬϲ 
signaling in the biofilm systems, liquid chromatography/mass spectrometry (LC/MS) was ϮϬϳ 
employed to detect the pseudomonal signaling molecules, C4- and 3-oxo-C12-acyl ϮϬϴ 
homoserine lactones (AHLs).  AHL levels were determined at 30 and 48 h for PAO1 cells ϮϬϵ 
grown in both MH and AS medium.  Initial experiments compared growth in MH and AS ϮϭϬ 
medium at 30 h (as at earlier time points in AS medium, AHLs were at the limits of detection; Ϯϭϭ 
results not shown).  LC/MS values indicated a reduction in the production of both 3-oxo-C12-ϮϭϮ 
AHL and C4-AHL signaling molecules in AS medium (62 and 783 fold respectively) Ϯϭϯ 
compared to MH medium (Fig. 4B).  Further experiments were performed on OligoG CF-Ϯϭϰ 
5/20-treated cultures grown in AS medium for 30 and 48 h (corresponding to mid- and late-Ϯϭϱ 
stationary phase respectively; results not shown).  Interestingly, in this model it was evident Ϯϭϲ 
that OligoG CF-5/20 (0.2-2%) induced a dose-dependent decrease in 3-oxo-C12 AHL Ϯϭϳ 
(produced by the Las pathway) in comparison to the control at 30 and 48 h (Fig. 4C), but did Ϯϭϴ 
ϭϬ 
 
not induce any significant change in C4-AHL (produced by the RhlI pathway; Fig. 4D).  Ϯϭϵ 
Although OligoG CF-5/20 had a significant effect on biofilm formation, there was no marked ϮϮϬ 
difference in ATP production (cell viability) by PAO1 or NH57388A following treatment (Fig. ϮϮϭ 
4E and 4F).   ϮϮϮ 
 ϮϮϯ 
The antibiotic properties of colistin were retained in artificial sputum medium when ϮϮϰ 
combined with OligoG CF-5/20 ϮϮϱ 
Assays of biofilm disruption in established (24 h) non-mucoid (PAO1) and mucoid ϮϮϲ 
(NH57388A) pseudomonal biofilms following 24 h treatment with OligoG CF-5/20 and/or ϮϮϳ 
colistin were investigated in AS medium.  The observed MIC value for colistin was 4x greater ϮϮϴ 
in AS medium (0.4 µg/ml versus 0.1 µg/ml) compared to MH medium. The MIC employed in ϮϮϵ 
subsequent studies was based upon these findings. ϮϯϬ 
As observed previously, PAO1 and NH57388A demonstrated the formation of large Ϯϯϭ 
numbers of spherical microcolonies, with extensive EPS in this model (Fig. 5A, 5B).  The ϮϯϮ 
mucoidal NH57388A biofilms were characterized by smaller microcolonies when compared Ϯϯϯ 
to PAO1 (median diameter 11 µm versus 14 µm respectively) (Fig. 5C, 5D).  Biofilm Ϯϯϰ 
treatment with colistin (at x4 the MBEC value (32), induced disruption of PAO1 and Ϯϯϱ 
NH57388A bacterial networks.  The microcolonies, however, remained intact (with no Ϯϯϲ 
change in median diameter; p>0.05).  In contrast, treatment with 2% OligoG CF-5/20 Ϯϯϳ 
induced significant decreases in the median microcolony diameter (6.λ ±2.0 µm and 6.1 ±2.7 Ϯϯϴ 
µm; PAO1 and NH57388A respectively; p<0.05) characterized by marked disruption of the Ϯϯϵ 
inter-colony networks and microcolony morphology.  Combining OligoG CF-5/20 with colistin ϮϰϬ 
(although not as effective as OligoG CF-5/20 alone on the mucoid strain) effectively Ϯϰϭ 
disrupted both microcolony structure (reducing the median diameter by 60% in PAO1) as ϮϰϮ 
well as the inter-colony branching/bridging in both mucoid and non-mucoid models.  Overall Ϯϰϯ 
structural differences can be seen at a lower magnification in Fig. S2. Ϯϰϰ 
 Ϯϰϱ 
ϭϭ 
 
 Ϯϰϲ 
DISCUSSION   Ϯϰϳ 
The improved survival of CF patients, due in part to the chronic administration of antibiotics, Ϯϰϴ 
has compounded the problems associated with resistance to antibiotic treatment (35, 36).  Ϯϰϵ 
With the rapid emergence of antibiotic resistance, the development of new therapies is ϮϱϬ 
essential.  Increased antibiotic resistance in biofilms has been extensively described, with Ϯϱϭ 
biofilms shown to resist antibiotics by up to 1000 fold (37).  These studies demonstrate the ϮϱϮ 
potential benefits of combination therapies using a novel mucolytic alongside conventional Ϯϱϯ 
antibiotics in the treatment of antibiotic-resistant, microcolony-forming Pseudomonas sp. Ϯϱϰ 
lung Infections.   Ϯϱϱ 
The resurgence of interest in colistin, a highly-effective membrane-permeabilizing Ϯϱϲ 
antibiotic, reflects the failure of conventional antibiotics in MDR infections (25).  Ϯϱϳ 
Unfortunately, the emergence of plasmid-mediated colistin resistance provides the imminent Ϯϱϴ 
possibility for horizontal gene transfer from veterinary to human pathogens (38).  Due to the Ϯϱϵ 
high rate of MDR in P. aeruginosa (3λ) colistin is now regarded as an antibiotic of ‘last resort’ ϮϲϬ 
and its use (in non-CF patients) is therefore limited to prevent further development of Ϯϲϭ 
resistance (40). ϮϲϮ 
Colistin acts through positively-charged electrostatic interactions with the negatively-Ϯϲϯ 
charged bacterial lipopolysaccharide (LPS), facilitating membrane disruption.  The observed Ϯϲϰ 
lowering of the efficacy of colistin in AS medium may, therefore, not only relate to an altered Ϯϲϱ 
growth rate in this environment, (which mimics growth conditions in the CF lung), but also Ϯϲϲ 
may be due to LPS modification and/or direct binding by mucin in the AS medium, effectively Ϯϲϳ 
‘sequestering’ free antibiotic (41).  This EPS effect, and the apparent differences in MIC for Ϯϲϴ 
colistin-treated NH57388A, (with MIC values being 4X greater in AS versus MH medium) Ϯϲϵ 
reflect the 104-fold difference previously observed between MIC (0.0λ4 µg/ml) and MBEC ϮϳϬ 
(>512 µg/ml) values for NH57388A in vitro (42).   Ϯϳϭ 
ϭϮ 
 
Within the diseased CF lung, >λ5% of P. aeruginosa exist in dense microcolonies, >5 ϮϳϮ 
µm from the epithelial cell-surface and independent of cell-surface attachment (14, 43).  The Ϯϳϯ 
microcolonies develop in the early stages of lung infection and readily resist physical Ϯϳϰ 
disruption (43).  The AS medium employed here induced pseudomonal microcolony Ϯϳϱ 
formation in both non-mucoid and mucoid strains as seen previously.  These microcolonies Ϯϳϲ 
resembled those observed in a range of CF epidemic and non-epidemic P. aeruginosa Ϯϳϳ 
strains (16); SEM demonstrating bridges between the microcolonies which appeared to be Ϯϳϴ 
composed of elongated single-cells encased in EPS, as previously observed in flow-cell Ϯϳϵ 
systems (44).  OligoG CF-5/20 was able to modulate both the size and structure of these ϮϴϬ 
bacterial microcolonies.  This may relate to its ability to interact with the EPS component of Ϯϴϭ 
the biofilm, by direct effects on the pseudomonal bacterial cell-surface, and on bacterial ϮϴϮ 
growth (2λ, 30).  Whilst imaging studies demonstrated that colistin effectively disrupted the Ϯϴϯ 
inter-colony bridges, the microcolonies (which were encased in EPS) appeared unaffected Ϯϴϰ 
by colistin alone.   Ϯϴϱ 
Despite the possible charge interactions between the cationic peptide colistin (41) Ϯϴϲ 
and the anionic OligoG CF-5/20 (30), colistin retained its antibiotic activity in the presence of Ϯϴϳ 
OligoG CF-5/20.  The ability of OligoG CF-5/20 to modify biofilm assembly in Pseudomonas Ϯϴϴ 
spp. has previously been attributed to irreversible binding at the bacterial cell surface (30).  Ϯϴϵ 
Moreover, the ability of OligoG CF-5/20 to potentiate the effectiveness of colistin against ϮϵϬ 
mucoid NH57388A biofilms by OligoG CF-5/20 has recently been demonstrated in MBEC Ϯϵϭ 
assays (32).  ϮϵϮ 
In this model, the ability of OligoG CF-5/20 (both alone, and more markedly with Ϯϵϯ 
colistin) to effectively disrupt the EPS of established biofilms was clearly evident.  Disruption Ϯϵϰ 
of the tight EPS-network, which comprises >λ0% of the biofilm dry-weight (45), has been Ϯϵϱ 
shown to lead to less mechanically-stable biofilms, which are then more susceptible to Ϯϵϲ 
antibiotics (46).  It appears therefore that EPS disruption by OligoG CF-5/20 maintained the Ϯϵϳ 
antimicrobial action of colistin by reducing its ability to bind to components of the biofilm Ϯϵϴ 
ϭϯ 
 
matrix, thereby increasing its penetration through the biofilm, facilitating access of colistin to Ϯϵϵ 
the pseudomonal cell membrane.   ϯϬϬ 
Initial experiments demonstrated the contrasting growth phenotype between freshly ϯϬϭ 
isolated clinical strains compared to the well-characterized reference strains.  Compensatory ϯϬϮ 
mutations in the clinical CF isolates are thought to provide differential fitness benefits, which ϯϬϯ 
are advantageous within the CF lung environment (47).  Fitness ’trade-offs’, where beneficial ϯϬϰ 
adaptations that improve fitness under one environmental condition that may lead to ϯϬϱ 
compensatory loss of other traits have been described (48).  This may, in part, explain the ϯϬϲ 
observed lower growth rate of fresh clinical isolates (adapted to the CF lung) when ϯϬϳ 
compared to the laboratory-maintained IPARP CF strains.  This variability highlights the ϯϬϴ 
importance of utilizing the reference strain collection for therapeutic development to ensure ϯϬϵ 
global standardization of in vitro testing.   ϯϭϬ 
A number of approaches have been attempted to modify biofilm EPS and facilitate ϯϭϭ 
treatment or displacement therapy.  These have includedμ use of bacterial polysaccharides ϯϭϮ 
e.g. from marine Vibrio sp. (4λ); co-administration of alginate lyase with DNase, which has ϯϭϯ 
been reported to increase the efficacy of antibiotics in reducing biofilm growth (50) and co-ϯϭϰ 
administration of antibiotics with alginate lyase to eliminate mucoid variants not affected by ϯϭϱ 
antibiotics alone (51).  Interestingly, we have also previously demonstrated synergy between ϯϭϲ 
OligoG CF-5/20 and rhDNase I in modifying the mechanical and structural properties of CF ϯϭϳ 
sputum (31).   ϯϭϴ 
Biofilms also contain bacterially-derived alginates which, in contrast to OligoG CF-5/20, ϯϭϵ 
lack G-blocks and have a considerably higher molecular mass (52).  Anionic EPS ϯϮϬ 
components, such as carboxyl groups, interact strongly with multivalent cations such as ϯϮϭ 
Ca2+, resulting in robust biofilms (53).  Sletmoen et al., (2012) demonstrated that alginate ϯϮϮ 
oligomers may destabilize the interaction between high Mw bacterially-produced alginates ϯϮϯ 
and mucin.  The ionic displacement of divalent cations e.g. Ca2+ has been described as a ϯϮϰ 
mechanism by which antimicrobial cationic peptides can potentiate antibiotics (54).  ϯϮϱ 
Similarly, the anionic alginate G-blocks may displace divalent cations associated with the ϯϮϲ 
ϭϰ 
 
biofilm, resulting in a weaker biofilm structure.  CD spectroscopy has previously been used ϯϮϳ 
to investigate the structural and conformational changes of polysaccharides containing ϯϮϴ 
uronic acid residues, and has recently been employed to characterize homopolymeric ϯϮϵ 
fractions of the linear co-polymers L-guluronate and D-mannuronate (34, 55).  The gelation ϯϯϬ 
of alginate in the presence of divalent cations such as Ca2+ in homopolyguluroinc acid is ϯϯϭ 
known to induce changes in the coordination of the carboxylate groups (56).  However, CD ϯϯϮ 
spectra indicated that the orientation of the carboxy groups monitored at ~210 nm were not ϯϯϯ 
changed upon mixing OligoG CF-5/20 with high Mw alginate. ϯϯϰ 
Previous studies in planktonic systems demonstrated that OligoG CF-5/20 modified both ϯϯϱ 
pilE gene expression and bacterial motility in Pseudomonas aeruginosa (30), which are ϯϯϲ 
controlled by QS.  The finding that levels of P. aeruginosa AHL signaling molecules were ϯϯϳ 
significantly reduced in AS medium compared to MH medium was perhaps unsurprising, ϯϯϴ 
reflecting the change in growth/morphology.  Sriramulu et al (2005), demonstrated the ϯϯϵ 
importance of lasR for the formation of the dense microcolony phenotype and these data ϯϰϬ 
demonstrated the ability of (>2%) OligoG CF-5/20 to significantly reduce 3-oxo-C12-AHL ϯϰϭ 
production at both mid- and late-stationary phase growth (30 and 48 h).  The lack of an ϯϰϮ 
observed effect on the Rhl product, C4-AHL, may reflect the reduced expression of rhlR ϯϰϯ 
which is known to occur in AS medium (16).  ϯϰϰ 
These experiments demonstrate that the previously described antibacterial effects of ϯϰϱ 
OligoG CF-5/20, are evident in this pseudomonal microcolony assay system which more ϯϰϲ 
closely resembles growth in the CF lung.  It must be remembered that many of the ϯϰϳ 
components of the in vivo lung are absent in the biofilm model, including lactoferrin, lipids ϯϰϴ 
and oligopeptides, which may modulate bacterial behavior in vivo.  OligoG CF-5/20 was ϯϰϵ 
shown to disrupt the biofilm EPS network and, in combined respiratory therapies, this ϯϱϬ 
inhaled treatment may facilitate increased access of therapeutic agents to bacteria and/or ϯϱϭ 
the lung cell-surface.  The mechanistic studies showed that this disruption of EPS structure ϯϱϮ 
was not simply related to interaction between the OligoG CF-5/20 and the pseudomonal (M-ϯϱϯ 
block alginate), but may rather reflect modification of QS signaling within the biofilm.  The ϯϱϰ 
ϭϱ 
 
findings here, and the proven safety of the agent as an inhalational therapy ϯϱϱ 
(www.clinicaltrials.gov, Identifierμ NCT00λ70346 and NCT0146552λ), highlight the potential ϯϱϲ 
utility of this agent in the treatment of MDR bacterial infections in a range of human ϯϱϳ 
diseases.  Phase IIb human studies are currently ongoing (www.clinicaltrials.gov, Identifierμ ϯϱϴ 
NCT02157λ22 and NCT0245378λ). ϯϱϵ 
 ϯϲϬ 
 ϯϲϭ 
METHODS ϯϲϮ 
Bacterial strains and media ϯϲϯ 
P. aeruginosa strains were cultured on blood agar plates and grown overnight in Tryptone ϯϲϰ 
soy broth (TSB; LabM), at 37°C.  Mueller Hinton (MH) medium or Artificial Sputum (AS) ϯϲϱ 
medium (adapted from earlier studies [43] by supplementation with 20 ml/L RPMI 1640 as ϯϲϲ 
an amino acid source; Sigma Aldrich) were also employed.   ϯϲϳ 
Reference strains (n=7) were obtained from the International P. aeruginosa ϯϲϴ 
Reference Panel (IPARP) (57) includingμ AA2 and AA44 (early and late non-mucoid CF ϯϲϵ 
colonizers respectively); AA43 (mucoidal colonizer from the same AT code) and mucoidal ϯϳϬ 
CF isolates, IST 27 (Lisbon, Portugal) and 21λ2 (source ID; Boston, MA).  The well ϯϳϭ 
characterized non-mucoid PAO1 and mucoidal MDR CF strain NH57388A (Copenhagen, ϯϳϮ 
Denmark), were also used in subsequent experiments. ϯϳϯ 
 ϯϳϰ 
Patients and clinical isolates  ϯϳϱ 
Newly isolated, non-mucoid P. aeruginosa strains (22078, 22554, and 22476) were obtained ϯϳϲ 
from induced sputum collected from children attending the Cystic Fibrosis Unit at the ϯϳϳ 
University Hospital of Wales, Cardiff participating in the Sputum Induction Trial (SpIT) study ϯϳϴ 
(a longitudinal sputum collection study in CF patients; LREC approved [project ID ϯϳϵ 
11/RPM/5216]).  ϯϴϬ 
 ϯϴϭ 
ϭϲ 
 
Changes in antibiotic susceptibility in the different media ϯϴϮ 
Bacteriocidal values for colistin in MH and AS medium were studied using standard ϯϴϯ 
minimum inhibitory concentration (MIC) assays as previously described (2λ). ϯϴϰ 
 ϯϴϱ 
Effects of OligoG CF-5/20 on pseudomonal growth in the presence of colistin ϯϴϲ 
For the inoculum for the pseudomonal growth curves, overnight cultures in TSB (n=3) were ϯϴϳ 
standardized to 106 cells/ml in MH medium.  For treated samples, P. aeruginosa ϯϴϴ 
(NH57388A; n=3) standardized to 108 cells/ml in MH medium were treated with and without ϯϴϵ 
2% OligoG CF-5/20 (w/v) ± colistin (0.5x MIC; 0.05 µg/ml).  Samples were grown (24 h; ϯϵϬ 
37°C) in λ6-well plates and change in cell density recorded every hour (OD600) on a ϯϵϭ 
FLUOstar Omega plate reader.  Cell doubling time was calculated for each growth curve. ϯϵϮ 
  ϯϵϯ 
Viable microbial cell numbers in culture when treated with OligoG CF-5/20 ϯϵϰ 
Adenosine triphosphate (ATP) production by PAO1 and NH57388A was compared in MH ϯϵϱ 
and AS medium ± 2% OligoG CF-5/10.  Cultures were prepared as for the growth curve ϯϵϲ 
experiments and analyzed using the BacTiter-Glo™ Microbial Cell Viability Assay (Promega) ϯϵϳ 
at 0, 2, 4, 6, 8, 12, 24 and 48 h with luminescence read on a FLUOstar Omega plate reader.   ϯϵϴ 
 ϯϵϵ 
Confocal laser scanning microscopy biofilms in MH and AS media in the presence of ϰϬϬ 
OligoG CF-5/20 ϰϬϭ 
Pseudomonal cultures (NH57388A) standardized to 107 cfu/ml, were inoculated 1μ20 ϰϬϮ 
in MH or AS media and incubated (37°C; 20 rpm) for 24 h or 48 h respectively in Greiner ϰϬϯ 
glass-bottomed optical λ6-well plates; the difference in growth rates in the two media, ϰϬϰ 
accounting for the longer growth time used for the AS medium.  For antimicrobial treatment, ϰϬϱ 
half of the supernatant was gently removed and replaced with fresh MH or AS medium ± 2% ϰϬϲ 
OligoG CF-5/20 and/or colistin at half the MBEC (2 µg/ml) and incubated for 1 h.  ϰϬϳ 
ϭϳ 
 
Supernatant was then removed and replaced with 6% (v/v) LIVE/DEAD® (Invitrogen) stain in ϰϬϴ 
PBS prior to imaging.  CLSM was performed using a Leica SP5 confocal microscope with ϰϬϵ 
x63 magnification under oil.  Z-stack CLSM images were analyzed using COMSTAT image ϰϭϬ 
analysis software (33).   ϰϭϭ 
AS medium biofilms were also fixed overnight at 4°C with 3% (v/v) glutaraldehyde ϰϭϮ 
and stained (1 h) at room temperature with 0.15% Syto-λ (Invitrogen) in PBS.  CLSM of Z-ϰϭϯ 
stack images was achieved using sequential fluorescence recordings of Syto-λ (Ȝex/Ȝem maxμ ϰϭϰ 
480/500nm) and propidium iodide (Ȝex/Ȝem maxμ 4λ0/635nm).   ϰϭϱ 
For EPS imaging, NH57388A biofilms (48 h) were grown in AS medium in 12-well ϰϭϲ 
glass bottomed plates (No. 1.5; MatTek Corp. Ashland, MA, USA) ± 2 or 6% OligoG CF-ϰϭϳ 
5/20..  Biofilms were fixed with 2.5% glutaraldehyde in PBS overnight at 4oC.  Fixative was ϰϭϴ 
then removed and biofilms stained with Syto-λ (0.15% in PBS) and Concanavalin A, Alexa ϰϭϵ 
Fluor™ 633 Conjugate (100 µg/ml in PBS; Invitrogen) prior to CLSM imaging.   ϰϮϬ 
 ϰϮϭ 
Scanning electron microscopy of OligoG CF-5/20 treated biofilms in different media ϰϮϮ 
P. aeruginosa (PAO1 and NH57388A) cultures were adjusted to 107 cfu/ml in MH or AS ϰϮϯ 
medium and grown (37°C for 24 h or 48 h respectively at 20 rpm) in 12-well plate (Greiner ϰϮϰ 
Bio-One) on ThermanoxTM glass slides (Agar Scientific) ± OligoG CF-5/20 0.2%, 2% or 6% ϰϮϱ 
(w/v).  For the established (24 h) biofilm model, half the supernatant was gently removed ϰϮϲ 
and replaced with 2% OligoG CF-5/20 (v/v), colistin (x4 MBEC; 16 µg/ml), or combination ϰϮϳ 
treatment and incubated for 24 h.  Supernatant was removed and biofilms fixed with 2.5% ϰϮϴ 
(v/v) glutaraldehyde prior to being washed (x4) with dH2O and freeze-dried.  The samples ϰϮϵ 
were then gold-coated and imaged using a Tescan Vega conventional SEM (2.5 kV) for ϰϯϬ 
untreated samples and the established biofilm model or performed using a Hitachi S4800 (1 ϰϯϭ 
kV) scanning electron microscope (SEM) for the biofilm development model.  Pseudo-ϰϯϮ 
coloring of SEM images was performed using Adobe Photoshop CS6 (Adobe Systems ϰϯϯ 
ϭϴ 
 
Europe Ltd, Maidenhead, UK).  ImageJ was used to measure microcolony diameter ϰϯϰ 
following line calibration using the known set scale for each image.  Measurements of the ϰϯϱ 
three largest cellular aggregates in each image were taken at the narrowest diameter.   ϰϯϲ 
 ϰϯϳ 
Direct interaction of OligoG CF-5/20 and pseudomonal high molecular weight alginate ϰϯϴ 
using circular dichroism spectroscopy ϰϯϵ 
CD spectra of OligoG CF-5/20, high Mw alginate (approx. 100 kDa) comprising 7% guluronic ϰϰϬ 
acid derived from Pseudomonas aeruginosa, and mixtures thereof were recorded using an ϰϰϭ 
Aviv Model 215 instrument (Aviv Biomedical, Lakewood, NJ, U.S.A.).  Samples were ϰϰϮ 
dissolved in 100 mM NaCl, 5 mM Tris.Cl, pH 7.5, spun at 14,000 g for 30 min at 4°C, and ϰϰϯ 
the supernatant transferred to a 0.1-cm quartz cell pre-warmed to 37°C.  Repetitive spectra ϰϰϰ 
were collected from 245 to 1λ6 nm at 0.2 nm intervals with 2 s accumulation per point ϰϰϱ 
corresponding to ~11 min/spectrum).  Buffer baselines were subtracted and ellipticities (Θ) ϰϰϲ 
were corrected for dilutions.  ϰϰϳ 
  ϰϰϴ 
Changes in quorum sensing acyl-homoserine lactone (AHL) production in different ϰϰϵ 
media when treated with OligoG CF-5/20  ϰϱϬ 
Overnight cultures of P. aeruginosa PAO1 were diluted (1μ100) in either MH or AS medium ϰϱϭ 
and grown for a further 30 or 48 h ± 0.2 or 2 % OligoG CF-5/20.  Cultures were washed (x3; ϰϱϮ 
18,000 g, 20 min, 4°C) in ice cold 0.λ% NaCl and pelleted cells were dried (80°C) for 24 h ϰϱϯ 
and weighed.  Culture supernatants were vigorously mixed (30 s) in equal volumes of ethyl ϰϱϰ 
acetate (acidified with 0.5% formic acid), and the upper layer collected (x3). The resultant ϰϱϱ 
ethyl acetate fractions were allowed to evaporate and the precipitate was re-suspended in 1 ϰϱϲ 
ml of distilled H2O (58).  Samples were freeze-dried prior to analysis.  Quantification of acyl ϰϱϳ 
ϭϵ 
 
homoserine lactones was done using high performance liquid chromatography triple ϰϱϴ 
quadrupole mass spectrometry (LC-QQQ-MS). ϰϱϵ 
Freeze-dried samples were maintained on ice and reconstituted in acetonitrile (200 ϰϲϬ 
µl) with 0.1% acetic acid and 7.2 ng ml-1 of the internal standard umbelliferone.  Samples ϰϲϭ 
were centrifuged (16,100 g, 10 min, 4°C) and supernatants filtered (0.4 ȝm; x2).  Samples (5 ϰϲϮ 
ȝl) were loaded onto a C18 XDB Eclipse (1.8 µm, 4.6 x 50 mm) reverse phase column and ϰϲϯ 
quantified using a 1200 series HPLC coupled to a 6410B enhanced sensitivity triple ϰϲϰ 
quadrupole (QQQ) mass spectrometer (Agilent Technologies, Palo Alto, USA).  For ϰϲϱ 
detection using positive ion mode, mobile phase A comprised of 5 mM ammonium acetate in ϰϲϲ 
water modified with 0.1% acetic acid and B was acetonitrile containing 0.1% acetic acid.  ϰϲϳ 
The column was equilibrated in 2% B before increasing in a linear fashion to 100% over 6 ϰϲϴ 
mins.  100% B was maintained for a further 2 min before column re-equilibration.  The ϰϲϵ 
column temperature was maintained at 35°C for the duration with a flow rate of 0.3 mL/min.  ϰϳϬ 
Source parameters were set as followsμ Temperature, 350°C; gas flow, 10 L/min; nebulizer, ϰϳϭ 
35 psi; and capillary voltage, 4 kV.  Data was analysed using Agilent MassHunter QQQ ϰϳϮ 
Quantitative Analysis software (Version B.07.00).  Peak areas were normalized to the ϰϳϯ 
internal standard umbelliferone and concentrations calculated using standard concentration ϰϳϰ 
curves, offset against blank values (the average peak areas for the blanks). ϰϳϱ 
 ϰϳϲ 
Statistical analysis ϰϳϳ 
The COMSTAT data was normally distributed so a standard t-test was performed using ϰϳϴ 
MiniTab 17 (Minitab Ltd, Coventry, UK) and a Bonferroni correction.  A one-way ANOVA was ϰϳϵ 
used for the AHL data using GraphPad 3 (La Jolla, CA, USA).  STATA was used to carry out ϰϴϬ 
a Kruskal-Wallis non-parametric test supplemented using Dunn’s test for the microcolony ϰϴϭ 
SEM measurements. ϰϴϮ 
 ϰϴϯ 
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FIGURE LEGENDS  ϰϵϱ 
FIG 1 Comparison of planktonic growth in MH medium of characterized and new cystic ϰϵϲ 
fibrosis P. aeruginosa isolates and biofilm growth following antimicrobial treatment.  Growth ϰϵϳ 
curves (24 h) of (A) Non-mucoid IPARP isolates (red) versus fresh clinical SpIT isolates ϰϵϴ 
(blue) and (B) non-mucoid IPARP isolates (red) versus mucoid (green).  (C) Growth curves ϰϵϵ 
of NH57388A (36 h) ± 2% and OligoG CF-5/20 with/without colistin (0.05 µg/ml).  Biofilm ϱϬϬ 
disruption assay showing LIVE/DEAD® CLSM [scale bar 20 µm] of 24 h established ϱϬϭ 
NH57388A biofilms, (D) untreated control, (E) 1 h colistin treatment, (F) 2% OligoG CF-5/20, ϱϬϮ 
(G) combined treatment.  COMSTAT analysis showing (H) mean height of biofilm and (I) ϱϬϯ 
ratio of DEADμ LIVE cells. (*p<0.05) ϱϬϰ 
 ϱϬϱ 
FIG 2 Comparison of growth of non-mucoid PAO1 and mucoid NH57388A P. aeruginosa in ϱϬϲ 
Mueller-Hinton (MH) and artificial sputum (AS) medium.  Scanning electron microscopy of ϱϬϳ 
bacterial growth in MH (24 h) and AS medium (48 h; scale bar 20 µm), with corresponding ϱϬϴ 
‘zoomed-in’ images in AS medium [scale bar 10 µm] (A) PAO1 and (B) NH57388A. (C) ϱϬϵ 
Ϯϭ 
 
Diagrammatic representation of biofilm structure in both media. (D) Cell viability (ATP ϱϭϬ 
production) of P. aeruginosa NH57388A and PAO1 (108 cfu/ml) grown in MH and AS ϱϭϭ 
medium. ϱϭϮ 
 ϱϭϯ 
FIG 3 Biofilm formation assays showing mucoid NH57388A P. aeruginosa biofilms grown in ϱϭϰ 
Mueller-Hinton (MH) and artificial sputum (AS) medium. SEM images of P. aeruginosa ϱϭϱ 
(NH57388A) biofilms grown ±OligoG CF-5/20 for (A) 24 h in Mueller Hinton (MH) medium; ϱϭϲ 
10 µm; (B), (C [zoomed in]) 48 h ± OligoG CF-5/20 [scale bar 5 µm] with (D) corresponding ϱϭϳ 
scatter graphs showing approx. mean microcolony size. (E) Corresponding CLSM EPS ϱϭϴ 
staining of P. aeruginosa (NH57388A) 48 h biofilms in artificial sputum (AS) medium using ϱϭϵ 
Syto-λ (green) and Concanavalin A 633 (red). (F,G) Biofilm disruption assay using Syto-λ ϱϮϬ 
(green) showing cross-sectional views of 48 h established biofilms treated I h with 2% ϱϮϭ 
OligoG CF-5/20 [scale bar 10 µm]. (*p<0.05). ϱϮϮ 
 ϱϮϯ 
FIG 4 Effect of OligoG CF-5/20 on high Mw alginate and on cell signaling molecules in vitro. ϱϮϰ 
(A) Circular dichroism (CD) spectra of high Mw pseudomonal alginate mixed with OligoG ϱϮϱ 
CF-5/20. Scans 1-7 show spectra of high Mw alginate (~20 ȝM) followed over ~77 min upon ϱϮϲ 
heating from 4 to 37⁰C; scans 8-11 (~44min) are recorded after addition of OligoG CF-5/20 ϱϮϳ 
(850 ȝM) followed by addition of Ca2+ (1mM) (scans 12-17, ~ 66min).  Spectra of OligoG CF-ϱϮϴ 
5/20 (850 ȝM) alone and its sum with high Mw alginate (20 ȝM) are shown as black and red ϱϮϵ 
dashed lines, respectively.  High performance liquid chromatography (HPLC) mass ϱϯϬ 
spectrometry (LC-QQQ-MS) to quantify acyl homoserine lactone (AHL; 3-oxo-C12-AHL and ϱϯϭ 
C4-AHL) production of P. aeruginosa PAO1 (B) grown in MH and AS medium (30 h), and in ϱϯϮ 
a time course assay (30 and 48 h) showing the effect of OligoG CF-5/20 on (C) 3-oxo C12-ϱϯϯ 
AHL and (D) C4-AHL (*p<0.05; n=3). Cell viability (ATP production) over 48 h of (E) PAO1 ϱϯϰ 
and (F) NH57388A grown in MH and AS medium ± 2% OligoG CF-5/20 (2%G). ϱϯϱ 
 ϱϯϲ 
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FIG 5 Biofilm disruption assays showing scanning electron microscopy (SEM) of ϱϯϳ 
antimicrobial (OligoG CF 5/20 and colistin) treated biofilms grown in ASM [Scale bar 10 µm]. ϱϯϴ 
SEM images of established (24 h) P. aeruginosa (A) PAO1 and (B) NH57388A biofilms ϱϯϵ 
treated for 24 h with 2% OligoG CF-5/20 ± colistin (16 µg/ml) with corresponding median ϱϰϬ 
microcolony diameter measurements for (C) PAO1 and (D) NH57388A (*p<0.05). ϱϰϭ 
 ϱϰϮ 
Supplementary Figures ϱϰϯ 
FIG S1 CD spectra of high Mw pseudomonal alginate mixed with OligoG CF-5/20.  Scans 1-ϱϰϰ 
2 show spectra of high Mw alginate (~20 ȝM) followed over ~22 min after heating from 4 to ϱϰϱ 
37°C, after which Ca2+ was added (scans 3-8μ cfinal = 1mM; scans λ-11μ cfinal = 2mM ). Oligo ϱϰϲ 
G CF-5/20 was added to cfin = 700ȝM (scans 12-15; molar ratio high Mw alginate to OligoG ϱϰϳ 
CF-5/20 1μ50) and cfin = 4.2mM (scans 16-22; molar ratio high Mw alginate to OligoG CF-ϱϰϴ 
5/20 1μ600).  Adding calcium to cfin = λ mM results in spontaneous alginate precipitation ϱϰϵ 
(scans 23-25). ϱϱϬ 
 ϱϱϭ 
FIG S2 Biofilm disruption assay showing SEM images of established (24 h) P. aeruginosa ϱϱϮ 
(A) PAO1 and (B) NH57388A biofilms treated for 24 10 h with 2% OligoG CF-5/20 ± colistin ϱϱϯ 
(16 ȝg/ml). Scale bar 20 ȝm. ϱϱϰ 
 ϱϱϱ 
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FIG 1 Comparison of planktonic growth in MH medium of characterized and new cystic
fibrosis P. aeruginosa isolates and biofilm growth following antimicrobial treatment.
Growth curves (24 h) of (A) Non-mucoid IPARP isolates (red) versus fresh clinical SpIT
isolates (blue) and (B) non-mucoid IPARP isolates (red) versus mucoid (green). (C)
Growth curves of NH57388A (36 h) ± 2% and OligoG CF-5/20 with/without colistin
(0.05 g/ml). Biofilm disruption assay showing LIVE/DEAD® CLSM [scale bar 20 µm]
of 24 h established NH57388A biofilms, (D) untreated control, (E) 1 h colistin
treatment, (F) 2% OligoG CF-5/20, (G) combined treatment. COMSTAT analysis
showing (H) mean height of biofilm and (I) ratio of DEAD: LIVE cells. (*p<0.05)
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FIG 2 Comparison of growth of non-mucoid PAO1 and mucoid NH57388A P. 
aeruginosa in Mueller-Hinton (MH) and artificial sputum (AS) medium.  Scanning 
electron microscopy of bacterial growth in MH (24 h) and AS medium (48 h; scale bar 
20 µm), with corresponding ‘zoomed-in’ images in AS medium [scale bar 10 µm] (A) 
PAO1 and (B) NH57388A. (C) Diagrammatic representation of biofilm structure in 
both media. (D) Cell viability (ATP production) of P. aeruginosa NH57388A and PAO1 
(108 cfu/ml) grown in MH and AS medium.
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FIG 3 Biofilm formation assays showing mucoid NH57388A P. aeruginosa biofilms grown in
Mueller-Hinton (MH) and artificial sputum (AS) medium. SEM images of P. aeruginosa
(NH57388A) biofilms grown ±OligoG CF-5/20 for (A) 24 h in Mueller Hinton (MH) medium; 10
µm; (B), (C [zoomed in]) 48 h ± OligoG CF-5/20 [scale bar 5 µm] with (D) corresponding scatter
graphs showing approx. mean microcolony size. (E) Corresponding CLSM EPS staining of P.
aeruginosa (NH57388A) 48 h biofilms in artificial sputum (AS) medium using Syto-9 (green) and
Concanavalin A 633 (red). (F,G) Biofilm disruption assay using Syto-9 (green) showing cross-
sectional views of 48 h established biofilms treated I h with 2% OligoG CF-5/20 [scale bar 10
µm]. (*p<0.05).
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FIG 4 Effect of OligoG CF-5/20 on high Mw alginate and on cell signaling molecules in vitro.
(A) Circular dichroism (CD) spectra of high Mw pseudomonal alginate mixed with OligoG
CF-5/20. Scans 1-7 show spectra of high Mw alginate (~20 μM) followed over ~77 min upon
heating from 4 to 37⁰C; scans 8-11 (~44min) are recorded after addition of OligoG CF-5/20
(850 μM) followed by addition of Ca2+ (1mM) (scans 12-17, ~ 66min). Spectra of OligoG
CF-5/20 (850 μM) alone and its sum with high Mw alginate (20 μM) are shown as black and
red dashed lines, respectively. High performance liquid chromatography (HPLC) mass
spectrometry (LC-QQQ-MS) to quantify acyl homoserine lactone (AHL; 3-oxo-C12-AHL and
C4-AHL) production of P. aeruginosa PAO1 (B) grown in MH and AS medium (30 h), and in
a time course assay (30 and 48 h) showing the effect of OligoG CF-5/20 on (C) 3-oxo C12-
AHL and (D) C4-AHL (*p<0.05; n=3). Cell viability (ATP production) over 48 h of (E) PAO1
and (F) NH57388A grown in MH and AS medium ± 2% OligoG CF-5/20 (2%G).
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FIG 5 Biofilm disruption assays showing scanning electron microscopy (SEM) of
antimicrobial (OligoG CF 5/20 and colistin) treated biofilms grown in ASM [Scale bar 10 µm].
SEM images of established (24 h) P. aeruginosa (A) PAO1 and (B) NH57388A biofilms
treated for 24 h with 2% OligoG CF-5/20 ± colistin (16 µg/ml) with corresponding median
microcolony diameter measurements for (C) PAO1 and (D) NH57388A (*p<0.05).
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